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Abstract
Background: Disruption of the lymphatic vasculature causes edema, inflammation, and end-tissue destruction. To assess
the therapeutic efficacy of systemic anti-inflammatory therapy in this disease, we examined the impact of a nonsteroidal
anti-inflammatory drug (NSAID), ketoprofen, and of a soluble TNF-a receptor (sTNF-R1) upon tumor necrosis factor (TNF)-a
activity in a mouse model of acquired lymphedema.
Methods and Findings: Lymphedema was induced by microsurgical ablation of major lymphatic conduits in the murine tail.
Untreated control mice with lymphedema developed significant edema and extensive histopathological inflammation
compared to sham surgical controls. Short-term ketoprofen treatment reduced tail edema and normalized the
histopathology while paradoxically increasing TNF-a gene expression and cytokine levels. Conversely, sTNF-R1 treatment
increased tail volume, exacerbated the histopathology, and decreased TNF-a gene expression. Expression of vascular
endothelial growth factor-C (VEGF-C), which stimulates lymphangiogenesis, closely correlated with TNF-a expression.
Conclusions: Ketoprofen therapy reduces experimental post-surgical lymphedema, yet direct TNF-a inhibition does not.
Reducing inflammation while preserving TNF-a activity appears to optimize the repair response. It is possible that the
observed favorable responses, at least in part, are mediated through enhanced VEGF-C signaling.
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Introduction
The lymphatic system is a vascular network that maintains
tissue fluid homeostasis and mediates regional inflammatory and
immune responses. In addition, the lymphatic system is an
important, but often overlooked, participant in cardiovascular
physiology and pathology [1]. When the anatomic and functional
integrity of the lymphatic vasculature is impaired, the resulting loss
of fluid transport capacity leads to lymphedema, the most readily
recognizable consequence of lymphatic vascular incompetence [2].
In lymphedema, regional disturbances in lymph transport lead to
progressive swelling of dependent tissues and ultimately to
permanent, disfiguring changes in tissue architecture.
Acquired lymphedema is a common and disabling state of
secondary vascular insufficiency, currently lacking satisfactory
pharmacotherapeutics. The potential for therapeutic lymphangio-
genesis has been supported by salutary responses to growth factors
in animal models of the disease [3–8]. However, enthusiasm for
the clinical use of these approaches must be tempered by the
significant role of cancer in acquired lymphedema [9] and by the
potential for enhanced lymph node metastasis [10–12].
We have characterized a mouse model of acute, acquired
lymphedema [5] that closely simulates the volume response,
histopathology, and lymphoscintigraphic characteristics of ac-
quired lymphedema [2,5,13–14]. This model is a useful experi-
mental platform for elucidating the mechanisms of the disease and
for evaluating potential therapies [15]. In previous studies, we
showed that administration of vascular endothelial growth factor
(VEGF)-C to promote therapeutic lymphangiogenesis reduced
edema volume and had beneficial effects on tissue architecture
[4,16]. Molecular characterization of whole-tissue homogenates
from mice with lymphedema revealed the prominence of
inflammatory mediators such as tumor necrosis factor (TNF-a)
[5], underscoring the inflammatory nature of this acquired
microvascular disorder. Lymph stasis alone cannot account for
the destructive tissue injury associated with lymphedema. The
inflammation in lymphedema may be a response to loss of
lymphatic vascular integrity and thus a rational target for
intervention.
In this study, we investigated the effects of two agents—
ketoprofen, a nonsteroidal anti-inflammatory drug (NSAID), and
pegsunercept, a modified soluble form of TNF-a receptor R1
(sTNF-R1)—in mice with surgically-induced lymphedema. Keto-
profen reduces inflammation by inhibiting cyclooxygenase but
paradoxically increases TNF-a levels [17–18]. sTNF-R1 directly
inactivates TNF-a and down-regulates TNF-a expression [19].
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regard to administration and dosing while achieving similar effects
on TNF-a [20]. Pegylation of the soluble TNF-a receptor
increases stability and half-life, addressing a limitation of first-
generation soluble receptor inhibitors [21]. Clinically, both classes
of antibody- and receptor-based anti-TNF-a drugs have similar
therapeutic properties [22]. Our goals were to assess the
therapeutic potential of systemic anti-inflammatory therapy and
to examine the specific effects of TNF-a modulation in a model of
acquired lymphedema.
Results
Lymphedema Is Reduced by NSAID and Exacerbated by
sTNF-R1
Changes in tail volume are shown in Figure 1. By day 3, tail
volume had increased modestly in all three surgical cohorts. On
day 7, however, tail volume was 158.0625.0% of baseline in
untreated mice with lymphedema (P,5610
27 vs sham surgery
controls), 139.868.5% in NSAID-treated mice (P,0.05 vs
lymphedema), and 183.7626.8% in sTNF-R1-treated mice
(P,0.005 vs lymphedema). Tail volume changes persisted until
sacrifice on day 11. sTNF-R1 had no discernable effect on tail
volume in normal and sham surgery mice (data not shown).
NSAID Therapy Normalizes Histological Changes in Mice
with Lymphedema
Qualitative and histomorphometric analysis of paraffin-embed-
ded, hematoxylin/eosin-stained skin sections obtained on day 11
revealed acute inflammatory changes in mice with untreated
lymphedema (Figure 2), as we have observed previously [4–5].
Normal controls had a thin dermis and epidermis and a normal
epidermal/dermal junction. In contrast, mice with untreated
lymphedema had hyperkeratosis, epidermal spongiosis and edema,
an irregular epidermal/dermal junction, elongated dermal papil-
lae, and a 2- to 3-fold expansion of tissue between the bone and
the epidermis. Epidermal thickness of lymphedema mice was
267.0629.3% of normal control mice (P,0.0005). In addition,
numerous dilated microlymphatics were evident in the dermis and
subdermis, and there was a notable increase in the number of
Figure 1. Tail volume response to pharmacotherapy. Changes in
tail volume are expressed as a percentage of the volume on day 0. By
day 7, lymphedema (LY) mice demonstrate significant increase in tail
volume. NSAID-treated lymphedema (LY-NSAID) mice were significantly
less edematous than normal controls (NL) or sham surgery control (SH)
mice. Conversely, sTNF-R1-treated lymphedema (LY-sTNF-R1) mice were
significantly more edematous. *P,0.05 vs LY,
{P,0.05 vs LY-NSAID.
doi:10.1371/journal.pone.0008380.g001
Figure 2. Histological responses to pharmacotherapy. Tail sections were harvested 16 mm from the base of the tail, stained with hematoxylin/
eosin, and examined by light microscopy. (A) Representative histology. Specimens from normal control (NL) mice, sham surgery control (SH) mice,
and lymphedema (LY) mice treated with either PBS, ketoprofen (NSAID), or the TNF-a inhibitor sTNFR-1. Untreated LY show hyperkeratosis, epidermal
spongiosis and edema, irregularity of the epidermal/dermal junction, elongation of the dermal papillae, and a 2- to 3-fold expansion of tissue
between the bone and the epidermis. There are numerous dilated microlymphatics and increased cellularity, including a large infiltration of
neutrophils. Treatment with NSAID normalizes these pathological findings whereas treatment with sTNFR-1 exacerbates the pathology. (B)
Quantification of epidermal thickness (ET). Changes in ET are expressed as a percentage of the average ET of NL. ET of NSAID-treated lymphedema
(LY-NSAID) mice was significantly reduced compared to untreated LY mice (P,0.0005) and were not significantly different than NL or SH control
mice. ET of sTNF-R1 treated lymphedema (LY-sTNF-R1) mice was significantly increased compared to untreated LY mice (P,0.05). *P,0.05 vs LY,
{P,0.0005 vs LY-NSAID.
doi:10.1371/journal.pone.0008380.g002
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There were no histological differences between sham surgery and
normal controls.
NSAID therapy resulted in normalization of histological
changes, including restoration of normal dermal-epidermal
architecture, disappearance of dilated microlymphatics, and
marked resolution of inflammatory changes. Epidermal thickness
was decreased 47.065.1% compared to untreated lymphedema
mice (P,0.0005) and not significantly different than normal
control mice. In contrast, sTNFR1 therapy produced no
discernible amelioration; indeed, the epidermal thickness of
sTNFR1-treated mice was significantly increased 16.062.5%
compared to untreated mice with lymphedema (P,0.05). Neither
therapy affected the histological appearance of post-mortem
specimens from normal and sham surgery controls.
Targeted Gene Expression Analysis by PCR
Differential expression of six targeted, representative genes was
quantitated by RT-PCR (Figure 3). Skin was harvested for RNA
extraction at the time of sacrifice, on day 11. TNF-a expression
was up-regulated in untreated lymphedema. NSAID treatment
further increased TNF-a expression (P,0.5), while treatment with
sTNF-R1 reduced TNF-a expression to control levels (P,0.05 vs
NSAID). A similar pattern of MCP-1 expression was observed.
The NSAID-induced up-regulation of these pro-inflammatory
cytokines was accompanied by significant, parallel up-regulation of
VEGF-C, VEGFR-3, and Prox1 expression. Expression of LYVE-
1 did not differ significantly among experimental cohorts.
Tissue Cytokine Analysis
In view of the disparate effects of the two systemic anti-
inflammatory treatments on relative TNF-a gene expression, we
quantitated tissue protein levels of this and other cytokines by
direct assay of tail skin homogenates (Figures 4 & 5). TNF-a tissue
levels were significantly higher in mice with NSAID-treated
lymphedema (P,0.005) than in normal controls or mice with
untreated or sTNF-R1-treated lymphedema. MCP-1 levels, too,
were elevated in untreated mice with lymphedema and were
further increased by NSAID and sTNF-R1 therapy (P,0.04).
MCP-3 levels were also elevated in lymphedema, but were
significantly reduced by both treatments (P,0.04). A similar
pattern was observed for macrophage inflammatory protein 1a.
Like TNF-a, eotaxin, a potent chemokine for neutrophils, was
increased by NSAID therapy (P,0.04) and decreased by sTNF-
R1 (P,0.05). The remaining cytokines assayed (TNF-b;
RANTES; interleukins 1a and b, 2–7, 10, and 23; interleukin 12
Figure 3. Targeted gene expression analysis by quantitative real-time PCR. Fold-changes of gene expression are relative to normal (NL)
controls on day 11. NSAID treatment significantly induced the expression of TNF-a, MCP-1, VEGF-C, VEGFR-3 and Prox1 in lymphedema (LY) mice. The
TNF-a inhibitor sTNF-R1 downregulated TNF-a but did not affect other genes. *P,0.05 vs LY,
{P,0.05 vs LY-NSAID.
doi:10.1371/journal.pone.0008380.g003
Figure 4. TNF-a levels in tissue homogenates of tail skin. Median
fluorescence intensity was used to assess the relative tissue concen-
trations of TNF-a. TNF-a levels were significantly higher in mice with
NSAID-treated lymphedema (LY-NSAID) (P,0.005) than in normal
controls or mice with untreated or sTNF-R1-treated lymphedema (LY-
sTNF-R1). *P,0.005 vs untreated lymphedema,
{P,0.005 vs LY-NSAID.
doi:10.1371/journal.pone.0008380.g004
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phage colony-stimulating factors; IP10; and VEGF-A) showed no
significant differences between treated and untreated lymphedema
cohorts.
Discussion
Effective treatment of acquired lymphedema will likely require
reversal of both lymphatic vascular insufficiency and inflamma-
tion. Our results indicate that systemic attenuation of inflamma-
tion and induction of pro-lymphangiogenic factors by the NSAID
ketoprofen is an effective therapy for experimental surgically-
induced lymphedema.
In the murine tail model, NSAID treatment lessens the
profound cellular and molecular inflammatory response that has
been described in clinical [2,14] and experimental lymphedema
[5,13]. We have demonstrated that systemic anti-inflammatory
therapy with ketoprofen can ameliorate lymphedema, but the
impact upon tissue edema was marginal. Full resolution of the
pathology and return to normal microvascular function appear to
require more than generic anti-inflammatory intervention alone.
Interestingly, the anti-inflammatory effects of ketoprofen were
accompanied by robust transcriptional and translational up-
regulation of TNF-a, consistent with in vitro and in vivo studies
that demonstrate the direct induction of TNF-a by NSAIDs [17],
including ketoprofen [23–24]. This relationship is said to
constitute a critical role in NSAID-related gastric intolerance
[25] and is thought to be mediated by the inhibition of
prostaglandin E2 [26–30], a feedback inhibitor of TNF-a
expression. NSAID use is associated with relapse of inflammatory
bowel disease [31], further suggesting that up-regulation of TNF-a
due to NSAID therapy is clinically relevant.
NSAID treatment significantly increased mRNA and protein
levels of TNF-a while other inflammatory mediators such as
MCP-3 and MIP1a were inhibited by NSAID treatment in
lymphedema mice. This may suggest that NSAID specifically
induces TNF-a while exerting otherwise anti-inflammatory effects.
MCP-3 is a pro-inflammatory b-chemokine bound by b-
Chemokine receptor D6 on a subset of lymphatics [32]. The
pattern of D6 expression on lymphatics suggests that it may
regulate chemokine-driven trafficking of leukocytes across lym-
phatics or during lymphangiogenesis [33]. Both NSAID and
sTNFR-1 treatment inhibited MCP-3 protein levels, supporting
their function as generally anti-inflammatory. The reduction of
edema volume after NSAID treatment suggests that anti-
inflammatory therapy may also facilitate the normalization of
lymphatic vascular function. However, the functional status of the
lymphatic vasculature in our model is not directly assessed. We
have previous published that MRI can be used to assess the
function of lymphatics [34], but the modality remains costly and
cumbersome. Functional assessment will be important to further
elucidate the mechanism of our observations in future studies.
Across all study categories, the increases in TNF-a mRNA and
protein levels correlated with increased expression of the pro-
lymphangiogenic factor VEGF-C and its cognate receptor,
VEGFR-3. Exogenous administration of VEGF-C lessens the
severity and slows the progression of experimental lymphedema,
including the murine tail model we used [3–4,16]. TNF-a
specifically induces VEGF-C [35–39] and Baluk et al. recently
reported that TNF-a induces lymphangiogenesis in a murine model
of airway inflammation [40]. While the effects of TNF-a appear to
directly affect the endothelium of the blood vasculature, effects on
the lymphatic system may require the inflammatory mediators of
recruited leukocytes. The role of the blood vasculature in our model
has yet to be explored fully, but the blood vascular growth factor
VEGF-A does not appear to be involved in our model. Unraveling
the complex interactions between the lymphatic and blood
vasculatures and the inflammatory response during lymph stasis
will be key to identifying specific targets of therapeutic intervention.
Our preliminary studies suggest that modulation of these processes
is a viable strategy that may yield clinically relevant therapies.
We found that direct inhibition of TNF-a by sTNF-R1
decreased VEGF-C and VEGFR-3 transcription and expression
and correlated with increased disease severity. These findings
suggest that TNF-a-mediated up-regulation of VEGF-C expres-
sion may be a protective mechanism following lymphatic injury.
TNF-a may be required for tissue repair and that it appears to
exert a permissive ameliorating effect in our model of acquired
lymphedema. We tested this hypothesis by inhibiting TNF-a,
which worsened the disease state. Although the mechanisms of
VEGF-C-mediated therapy can be debated [41], the positive
therapeutic response of augmented VEGF-C signaling can be
plausibly linked, at least in part, to enhanced lymphatic repair and
increased lymphatic function.
Our findings suggest that ketoprofen imparts its beneficial
therapeutic response by reducing inflammation and consequent
tissue edema. Ketoprofen may also promote VEGF-C-mediated
lymphangiogenesis through the induction of TNF-a (Figure 6).
This intriguing possibility requires further investigation. The
selection of ketoprofen as the agent-of-investigation may have been
fortuitous, insofar as the NSAID class of drugs exhibit myriad
pharmacological characteristics, with agents of varying IC50s and
degrees of COX-1, COX-2, and COX-independent mechanisms
of action. Extension of our results to other subclasses of NSAIDs
will be desirable in future investigations. In addition, whether
induction of the VEGF-C/VEGFR-3 axis results in increased
lymphatic function, increased de novo development of lymphatics,
or other alternative mechanisms of benefit is also not yet known
and warrants intensive study.
Lymphedema has the distinct morphological attributes of a
cutaneous inflammatory disorder [5]. We demonstrated that
Figure 5. Inflammatory cytokine levels in tissue homogenates
of tail skin. Median fluorescence intensity was used to assess the
relative tissue concentrations of MCP-1, MCP-3, MIP1a, Eotaxin, and
VEGF-A. MCP-1 levels were elevated in mice with lymphedema (LY) and
further increased by both ketoprofen and sTNF-R1 anti-inflammatory
treatments. MCP-3 levels were also elevated in lymphedema but were
significantly reduced by both treatments. A similar pattern was
observed for macrophage inflammatory protein 1a (MIP1a). Like TNF-
a, eotaxin levels were reduced by NSAID therapy and decreased by
sTNF-R1. No effect on the blood vascular growth factor VEGF-A was
observed. *P,0.04 vs to LY,
{P=0.05 vs LY,
{P,0.05 vs LY-NSAID.
doi:10.1371/journal.pone.0008380.g005
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rate lymphedema, but the response on end-tissue edema was
marginal. Full resolution of the pathology and return to normal
microvascular function appear to require more than generic anti-
inflammatory intervention alone. We propose that uncoupling the
deleterious manifestations of inflammation from the desired pro-
lymphangiogenic effects of endogenous repair mechanisms is a
logical therapeutic strategy. The present study represents a novel
and preliminary step toward the development of pharmacother-
apeutics for the treatment of acquired lymphedema.
Methods
This study was approved by the Administrative Panels on
Laboratory Animal Care of Stanford University.
Creation of Experimental Lymphedema
Tail lymphedema was induced in female hairless, immunocom-
petent SKH-1 mice (Charles River Laboratories, Boston, MA) as
described [5]. The mice were anesthetized with a solution of
ketamine, xylazine, and saline (0.07 ml i.p.). The skin of the tail was
circumferentially incised 16 mm distal to its base. The major
lymphatic trunks were identified by subcutaneous injection of
methylene blue distal to the incision and ablated by limited cautery.
The mice were carefully monitored for any visceral signs of distress.
Sham surgery controls were treated identically, but without
lymphatic cautery. Normal controls did not undergo any surgical
manipulation. All mice were sacrificed in accordance with
American Veterinary Medical Association guidelines for rodent
euthanasia after day 11 days of observation. After sacrifice, 500 mg
sections of the tail were harvested for paraffin embedding and RNA
extraction. For all in vivo experiments, housing, husbandry and
experimentation were in strict accordance with the Animal Welfare
Act and the Guide for the Care and Use of Laboratory Animals.
Treatment Protocols
Beginning on day 3 after the surgical manipulation, mice with
lymphedema received subcutaneous injections of NSAID (keto-
profen, 5 mg/kg; Sigma, St. Louis, MO) (n=12), sTNF-R1
(pegsunercept, 3 mg/kg; Amgen, Thousand Oaks, CA) (n=17), or
phosphate-buffered saline (PBS) (n=16) every other day until the
day of sacrifice. Sham surgery and normal controls were treated
identically with the NSAID (n=8 per group), sTNF-R1 (n=11
per group), or PBS (n=11 normal controls, n=8 sham surgery
controls).
Tail Volume Quantitation
Tail volume was measured serially in each mouse, using a digital
photographic application of the truncated cone approximation
[42] as described [43].
Histology
Immediately after sacrifice, 0.5-g sections of tail were harvested
for histological analysis and RNA extraction. Sections extended
from a point 4 mm proximal to the surgical incision to 8 mm
beyond it. The specimens were fixed overnight in 4% parafor-
maldehyde, embedded in paraffin, cut into 5-mm sections, stained
with hematoxylin and eosin (Richard-Allan Scientific, Kalamazoo,
MI), and examined by light microscopy.
Histomorphometric Quantitation
Epidermal thickness was measured serially using digital images
of histology slides stained with hematoxylin and eosin. Processing
and analysis were performed using Adobe Photoshop CS4 and
ImageJ (http://rsbweb.nih.gov/ij) as previously described with
modifications [44]. Quantitative measurements were imported to
Prism 5 software (GraphPad Software Inc., La Jolla, CA) for
statistical analysis and graphing.
Quantitative Real-Time RT-PCR
Quantitative real-time polymerase chain reaction (qRT-PCR)
was performed as previously described [45]. Primers and probes
were from Assays-on-Demand (Applied Biosystems, Foster City,
CA). cDNA was synthesized from 5 mg of total RNA with Taqman
reverse-transcription reagents (Applied Biosystems) and amplified
in triplicate at 50uC for 2 minutes and 95uC for 10 minutes,
followed by 40 cycles of 95uC for 15 seconds and 60uC for 1
minute. Reactions without template and/or enzyme were used as
negative controls. 18S ribosomal RNA served as an internal
control. A standard curve derived from embryonic mouse RNA
was plotted for each target gene by linear regression using SPSS
software (v. 11.0, Applied Biosystems). RNA quantity was
expressed relative to the corresponding 18S control. Fold
differences were calculated by dividing the experimental results
by the pooled normal results and were plotted on a log10 scale.
Tissue Cytokine Assays
Cytokine levels in tail skin were measured in normal controls
and mice with untreated, NSAID-treated, and sTNF-R1-treated
lymphedema (n=3 per group) sacrificed on postoperative day 7.
The Luminex LabMap200 System was used to measure the levels
of 42 cytokines from the supernatant of tissue homogenates.
Multiplex cytokine kits were purchased from Panomics (Fremont,
CA), and the assay was performed according to the manufacturer’s
recommendation with the following modifications: 25–50 mlo f
samples, standards, and controls were added in duplicate to 96-
well filter plates pre-configured with a panel of anti-cytokine
antibodies covalently linked to unique polystyrene beads. The
Figure 6. Model of inflammation and lymphedema. Loss of
lymphatic vascular integrity leads to diminished lymph transport, which
promotes both edema and inflammation. TNF-a, a potent mediator of
inflammation, is also a known inducer of the pro-lymphangiogenic
factor, VEGF-C. Both ketoprofen and pegsunercept have general
inhibitory effects on inflammation, ketoprofen promotes endogenous
repair mechanisms mediated by VEGF-C and VEGFR-3by simultaneous
inducing TNF-a. In contrast, pegsunercept directly inhibits TNF-a and
therefore exacerbates the disease state by disrupting pro-lymphangio-
genic processes driven by VEGF-C and VEGFR-3.
doi:10.1371/journal.pone.0008380.g006
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500 rpm, vacuum aspirated, and washed three times with 140 ml
of wash buffer to remove unbound antigen. Biotinylated detection
antibody solution (25 ml) was added to each well and incubated for
1 hour with shaking at 500 rpm at room temperature. The plate
was incubated with 50 ml of streptavidin-phycoerythrin for 35
minutes and then with 120 ml of reading buffer for 3 minutes at
room temperature with shaking. After laser excitation, digital
images of the bead array were captured with a CCD camera and
analyzed on a computer workstation with BeadView software.
Statistical analysis
Two-sample t tests (equal variance) and one-way ANOVA were
used to analyze the significance of difference for the tail volume,
gene expression, and cytokine assays. P,0.05 was considered
statistically significant. Standard deviations were calculated for all
data.
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